Article:
Non-alcoholic fatty liver disease (NAFLD) and immune response

creativeworkseries.issnISSN (Print) : 1993-2979 | ISSN (Online) : 1993-2987
dc.contributor.authorAdhikari, Khem Bahadur
dc.contributor.authorTirosh, Oren
dc.date.accessioned2026-06-12T06:00:23Z
dc.date.available2026-06-12T06:00:23Z
dc.date.issued2010
dc.descriptionKhem Bahadur Adhikari Department of Food Sciences, Institute for Technology and Storage of Agricultural Products, Agricultural ResearchOrganization, The Volcani Center, Bet Dagan, Israel Oren Tirosh Department of Food Sciences, Institute for Technology and Storage of Agricultural Products, Agricultural ResearchOrganization, The Volcani Center, Bet Dagan, Israel
dc.description.abstractAbstract Introduction: Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease that affects a high proportion of world’s population. This review aims to update latest advances in epidemiology, clinical aspects, pathogenesis, mechanism, immune responses and therapies of NAFLD. Methods: This paper was prepared with reviews of published articles and books. Results: NAFLD, the commonest liver disorder in the world, is closely associated with metabolic syndrome, particularly obesity and insulin resistance. Sedentary lifestyle and poor dietary choices are leading to obesity, subsequently increasing risk for developing metabolic syndrome and NAFLD. NAFLD is characterized with increased lipogenesis, defective mitochondrial and peroxisomal b-oxidation and/or disability to lipid export from the liver. It can progress to cirrhosis, hepatocellular carcinoma, and liver failure. The development and progression of NAFLD are also affected by diet and genetic factors. Poor immune system cannot overcome proinflammatory cytokines and reactive oxygen species (ROS) which cause oxidative liver injury. Up regulation of perioxisome proliferator activated receptor (PPAR) and disruption of sterol regulatory element binding protein (SREBP) are important targets for pharmacological intervention accompanied with lifestyle modifications. Conclusions: People with obesity, type 2 diabetes mellitus (T2DM), and metabolic syndrome are likely to suffer from NAFLD. Keywords: Cytokine, inflammation, NAFLD, obesity
dc.identifierhttps://doi.org/10.59779/jiomnepal.702
dc.identifier.urihttps://hdl.handle.net/20.500.14572/6453
dc.language.isoen_US
dc.publisherInstitute of Medicine
dc.subjectCytokine
dc.subjectinflammation
dc.subjectNAFLD
dc.subjectobesity
dc.titleNon-alcoholic fatty liver disease (NAFLD) and immune response
dc.typeArticle
dspace.entity.typePublication
local.article.typeReview Article
oaire.citation.endPage53
oaire.citation.startPage43
relation.isJournalIssueOfPublication33ea080e-1a01-4a26-8386-b6faa78f22b2
relation.isJournalIssueOfPublication.latestForDiscovery33ea080e-1a01-4a26-8386-b6faa78f22b2
relation.isJournalOfPublicationa9ba45d9-ee33-4a6b-b1fc-6626b87eec6c

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
43-53.pdf
Size:
343.8 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.86 KB
Format:
Item-specific license agreed to upon submission
Description:

Collections